ID: ALA3322341

Max Phase: Preclinical

Molecular Formula: C20H23NO7

Molecular Weight: 389.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(COc1ccc(-c2ccccc2)cc1)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

Standard InChI:  InChI=1S/C20H23NO7/c22-10-15-17(24)18(25)19(26)20(28-15)21-16(23)11-27-14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9,15,17-20,22,24-26H,10-11H2,(H,21,23)/t15-,17-,18+,19-,20-/m1/s1

Standard InChI Key:  NSADEBQKFSASLM-XIKSMUEASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.40

Molecular Weight (Monoisotopic): 389.1475

AlogP: -0.35

#Rotatable Bonds: 6

Polar Surface Area: 128.48

Molecular Species: NEUTRAL

HBA: 7

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.42

CX Basic pKa:

CX LogP: -0.06

CX LogD: -0.06

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.46

Np Likeness Score: 0.22

References

1. Parmenopoulou V, Kantsadi AL, Tsirkone VG, Chatzileontiadou DS, Manta S, Zographos SE, Molfeta C, Archontis G, Agius L, Hayes JM, Leonidas DD, Komiotis D..  (2014)  Structure based inhibitor design targeting glycogen phosphorylase B. Virtual screening, synthesis, biochemical and biological assessment of novel N-acyl-β-d-glucopyranosylamines.,  22  (17): [PMID:25092521] [10.1016/j.bmc.2014.06.058]

Source

Source(1):

• Scientific Literature